Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293162 | 1.00 | ALDH1A1 (0.37) | ALDH1A1DDAH1KMT2ATP53CYP4F2 | |
| SCHEMBL18787662 | 1.00 | ALDH1A1 (0.37) | ALDH1A1DDAH1KMT2ATP53CYP4F2 | |
| SCHEMBL5830956 | 0.94 | KMT2A (0.34) | ALDH1A1DDAH1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL21877045 | 0.94 | KMT2A (0.34) | ALDH1A1DDAH1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL29691714 | 0.86 | ALDH1A1 (0.43) | ALDH1A1DDAH1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL6665330 | 0.83 | KMT2A (0.39) | KMT2ATP53CYP4F2CYP4A11CYP1A2 | |
| SCHEMBL7080897 | 0.81 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL17928482 | 0.81 | MGAM (0.33) | ALDH1A1TSHRGAA | |
| SCHEMBL18334259 | 0.81 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL29211839 | 0.79 | GABRR1 (0.33) | TP53CYP4F2CYP4A11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041721-B2 | Highly neutralized polymer golf ball compositions including oxa acids and methods of making same | ACUSHNET COMPANY (US) | 2006-05-09 | — | — | US | claimed |
| EP-0910362-B1 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 2004-10-27 | — | — | EP | claimed |
| US-20030225197-A1 | Highly neutralized polymer golf ball compositions including oxa acids and methods of making same | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2003-12-04 | — | — | US | claimed |
| US-6534543-B2 | Topical compositions with carboxy acid/ester, amide, or thioester/thioacid groups, with one or more of ether, amine, or sulfide groups; for example 3,6-dioxaheptanioic acid; peeling skin, softening hair | AVON PRODUCTS, INC. | 2003-03-18 | — | — | US | claimed |
| US-20020040056-A1 | Oxa acids and related compounds for treating skin conditions | AVON PRODUCTS, INC. | 2002-04-04 | — | — | US | claimed |
| JP-2000511900-A | — | — | 2000-09-12 | — | — | JP | claimed |
| US-6069169-A | OXA acids and related compounds for treating skin conditions | AVON PRODUCTS, INC. (US) | 2000-05-30 | — | — | US | claimed |
| EP-0910362-A4 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 1999-12-22 | — | — | EP | claimed |
| EP-0910362-A1 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1999-04-28 | — | — | EP | claimed |
| US-5847003-A | Oxa acids and related compounds for treating skin conditions | AVON PRODUCTS, INC. (US) | 1998-12-08 | — | — | US | claimed |
| WO-1997046231-A1 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1997-12-11 | — | — | WO | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-6069169-A | OXA acids and related compounds for treating skin conditions | AVON PRODUCTS, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0910362-A4 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0910362-A1 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997046231-A1 | OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| CN-1016778-B | spiro-substituted glutaric acid monoamides | PFIZER LTD (GB) | 1992-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040056-A1 | Oxa acids and related compounds for treating skin conditions | OXGR1, OXA1L, CXCR1 | ALDH1A1 577/4885DDAH1 1574/4885KMT2A 3850/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ALDH1A1 2833/4885DDAH1 1686/4885KMT2A 1975/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ALDH1A1 2833/4885DDAH1 1686/4885KMT2A 1975/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | ALDH1A1 2777/4885DDAH1 1708/4885KMT2A 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.